Implications of polygenic risk for personalised colorectal cancer screening

Annals of Oncology

Volumn 27, Issue 3, 2016, Pages 429-434

  Frampton, M J E ^a   Law, P ^a   Litchfield, K ^a   Morris, E J ^b   Kerr, D ^c   Turnbull, C ^a,d   Tomlinson, I P ^e   Houlston, R S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Colorectal cancer; Personalised screening European Union 258236; Polygenic risk

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRAIT; GENETIC VARIABILITY; GENOME WIDE COMPLEX TRAIT ANALYSIS; HEALTH PROGRAM; HERITABILITY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; NATIONAL BOWEL SCREENING PROGRAM; NATIONAL HEALTH SERVICE; PERSONALISED SCREENING; POLYGENIC RISK SCORE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; ENGLAND; MASS SCREENING; MIDDLE AGED; PERSONALIZED MEDICINE; PROCEDURES; RISK; RISK FACTOR;

AGED; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; ENGLAND; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRECISION MEDICINE; RISK; RISK FACTORS;

EID: 84959893914     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv540     Document Type: Article

References (24)

1. CRU. Cancer Statistics-Bowel Cancer. 2015; http://www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/(10 October 2015, date last accessed).
2. Network NCI. Colorectal cancer survival by stage. 2014; http://wwwncinorguk/publications/data_briefings/colorectal_cancer_survival_by_stage (10 October 2015, date last accessed)
3. Programme NBCS. http://www.cancerscreening.nhs.uk/bowel/index.html (10 October 2015, date last accessed).
4. Programme BSSBS. http://www.bowelscreening.scot.nhs.uk/(10 October 2015, date last accessed).
5. Aaltonen L, Johns L, Jarvinen H et al. Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors. Clin Cancer Res 2007; 13: 356-361.
6. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010; 10: 353-361.
7. Pashayan N, Duffy SW, Chowdhury S et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011; 104: 1656-1663.
8. Garcia-Closas M, Gunsoy NB, Chatterjee N. Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. J Natl Cancer Inst 2014; 106.
9. Mavaddat N, Pharoah PD, Michailidou K et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 2015; 107.
10. Fay MP, Pfeiffer R, Cronin KA et al. Age-conditional probabilities of developing cancer. Stat Med 2003; 22: 1837-1848.
11. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 2011; 88: 76-82.
12. Dunlop MG, Dobbins SE, Farrington SM et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012; 44: 770-776.
13. Lee SH, Harold D, Nyholt DR et al. Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Hum Mol Genet 2013; 22: 832-841.
14. Moss SM, Campbell C, Melia J et al. Performance measures in three rounds of the English bowel cancer screening pilot. Gut 2012; 61: 101-107.
15. Young GP, Symonds EL, Allison JE et al. Advances in Fecal Occult Blood Tests: the FIT revolution. Dig Dis Sci 2015; 60: 609-622.
16. Mitchell RJ, Brewster D, Campbell H et al. Accuracy of reporting of family history of colorectal cancer. Gut 2004; 53: 291-295.
17. Mai PL, Garceau AO, Graubard BI et al. Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst 2011; 103: 788-797.
18. Houlston RS, Murday V, Harocopos C et al. Screening and genetic counselling for relatives of patients with colorectal cancer in a family cancer clinic. BMJ 1990; 301: 366-368.
19. Carney PA, O'Malley JP, Gough A et al. Association between documented family history of cancer and screening for breast and colorectal cancer. Prev Med 2013; 57: 679-684.
20. Cairns SR, Scholefield JH, Steele RJ et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010; 59: 666-689.
21. Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol 2013; 31: 2554-2562.
22. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96: 2992-3003.
23. Hall AE, Chowdhury S, Hallowell N et al. Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issues. J Public Health (Oxf) 2014; 36: 285-291.
24. Burn J, Gerdes AM, Macrae F et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-2087.